Treatment of borderline personality disorder

Potential of the new antipsychotic medications

S. Charles Schulz, Kelly L. Camlin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Since their introduction, the newer atypical antipsychotics have been tested in a number of areas besides schizophrenia. In this article, studies of their use in borderline personality disorder (BPD) are reviewed. The authors first discuss the clinical characteristics of BPD and outline the issues that need to be addressed in designing treatment trials for this disorder. They then review treatment studies in BPD using low doses of traditional antipsychotics. These studies demonstrated that the traditional antipsychotics were effective in BPD but were also difficult to tolerate, mainly because of extrapyramidal side effects. Because the newer antipsychotic medications appear to be easier to tolerate, researchers have begun testing these newer agents in BPD. The authors review the studies that have been done to date using the newer antipsychotics in the treatment of BPD and conclude that the results are promising and that the new medications may even offer some advantages (e.g., for affective symptoms) that go beyond being as effective as traditional antipsychotics but without the extrapyramidal side effects. The article concludes with a discussion of areas meriting future research.

Original languageEnglish (US)
Pages (from-to)247-255
Number of pages9
JournalJournal of Practical Psychiatry and Behavioral Health
Volume5
Issue number5
StatePublished - Sep 1 1999

Fingerprint

Borderline Personality Disorder
Antipsychotic Agents
Affective Symptoms
Schizophrenia
Research Personnel

Keywords

  • Atypical antipsychotics
  • Borderline personality disorder
  • Clozapine
  • Low-dose neuroleptic strategy
  • Olanzapine
  • Quetiapine
  • Risperidone
  • Traditional antipsychotics

Cite this

Treatment of borderline personality disorder : Potential of the new antipsychotic medications. / Schulz, S. Charles; Camlin, Kelly L.

In: Journal of Practical Psychiatry and Behavioral Health, Vol. 5, No. 5, 01.09.1999, p. 247-255.

Research output: Contribution to journalArticle

@article{79d90c2ec3574255a69ae50f50c8fd3a,
title = "Treatment of borderline personality disorder: Potential of the new antipsychotic medications",
abstract = "Since their introduction, the newer atypical antipsychotics have been tested in a number of areas besides schizophrenia. In this article, studies of their use in borderline personality disorder (BPD) are reviewed. The authors first discuss the clinical characteristics of BPD and outline the issues that need to be addressed in designing treatment trials for this disorder. They then review treatment studies in BPD using low doses of traditional antipsychotics. These studies demonstrated that the traditional antipsychotics were effective in BPD but were also difficult to tolerate, mainly because of extrapyramidal side effects. Because the newer antipsychotic medications appear to be easier to tolerate, researchers have begun testing these newer agents in BPD. The authors review the studies that have been done to date using the newer antipsychotics in the treatment of BPD and conclude that the results are promising and that the new medications may even offer some advantages (e.g., for affective symptoms) that go beyond being as effective as traditional antipsychotics but without the extrapyramidal side effects. The article concludes with a discussion of areas meriting future research.",
keywords = "Atypical antipsychotics, Borderline personality disorder, Clozapine, Low-dose neuroleptic strategy, Olanzapine, Quetiapine, Risperidone, Traditional antipsychotics",
author = "Schulz, {S. Charles} and Camlin, {Kelly L.}",
year = "1999",
month = "9",
day = "1",
language = "English (US)",
volume = "5",
pages = "247--255",
journal = "Journal of Psychiatric Practice",
issn = "1527-4160",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Treatment of borderline personality disorder

T2 - Potential of the new antipsychotic medications

AU - Schulz, S. Charles

AU - Camlin, Kelly L.

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Since their introduction, the newer atypical antipsychotics have been tested in a number of areas besides schizophrenia. In this article, studies of their use in borderline personality disorder (BPD) are reviewed. The authors first discuss the clinical characteristics of BPD and outline the issues that need to be addressed in designing treatment trials for this disorder. They then review treatment studies in BPD using low doses of traditional antipsychotics. These studies demonstrated that the traditional antipsychotics were effective in BPD but were also difficult to tolerate, mainly because of extrapyramidal side effects. Because the newer antipsychotic medications appear to be easier to tolerate, researchers have begun testing these newer agents in BPD. The authors review the studies that have been done to date using the newer antipsychotics in the treatment of BPD and conclude that the results are promising and that the new medications may even offer some advantages (e.g., for affective symptoms) that go beyond being as effective as traditional antipsychotics but without the extrapyramidal side effects. The article concludes with a discussion of areas meriting future research.

AB - Since their introduction, the newer atypical antipsychotics have been tested in a number of areas besides schizophrenia. In this article, studies of their use in borderline personality disorder (BPD) are reviewed. The authors first discuss the clinical characteristics of BPD and outline the issues that need to be addressed in designing treatment trials for this disorder. They then review treatment studies in BPD using low doses of traditional antipsychotics. These studies demonstrated that the traditional antipsychotics were effective in BPD but were also difficult to tolerate, mainly because of extrapyramidal side effects. Because the newer antipsychotic medications appear to be easier to tolerate, researchers have begun testing these newer agents in BPD. The authors review the studies that have been done to date using the newer antipsychotics in the treatment of BPD and conclude that the results are promising and that the new medications may even offer some advantages (e.g., for affective symptoms) that go beyond being as effective as traditional antipsychotics but without the extrapyramidal side effects. The article concludes with a discussion of areas meriting future research.

KW - Atypical antipsychotics

KW - Borderline personality disorder

KW - Clozapine

KW - Low-dose neuroleptic strategy

KW - Olanzapine

KW - Quetiapine

KW - Risperidone

KW - Traditional antipsychotics

UR - http://www.scopus.com/inward/record.url?scp=0001642445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001642445&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 247

EP - 255

JO - Journal of Psychiatric Practice

JF - Journal of Psychiatric Practice

SN - 1527-4160

IS - 5

ER -